Investigation of Pain Modulation Phenotypes in Female Patients With Fibromyalgia
研究概览
地位
详细说明
Fibromyalgia is characterized by altered pain processing mechanisms, including impaired descending pain inhibition and central sensitization. Although both mechanisms have been independently associated with symptom severity and functional impairment, their interrelationship and relative contributions to disease impact are not fully understood.
This study aims to examine the associations between conditioned pain modulation, central sensitization symptoms, and fibromyalgia impact. In particular, the study evaluates whether central sensitization symptoms act as a mediator in the relationship between impaired pain modulation and clinical disease burden. Participants with fibromyalgia are assessed using standardized clinical and psychological measures, including the Fibromyalgia Impact Questionnaire, Central Sensitization Inventory, and Hospital Anxiety and Depression Scale. Quantitative sensory testing is performed to evaluate conditioned pain modulation, pressure pain threshold, and temporal summation.Statistical analyses are conducted to explore bivariate associations and to identify independent predictors of fibromyalgia impact. A mediation framework is applied to assess whether central sensitization symptoms explain the relationship between pain modulation and clinical outcomes.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Feyza Nur Yücel, Assoc. Prof.
- 电话号码:+90 (0216) 542 20 00
- 邮箱:dr.fny28@gmail.com
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Having received a diagnosis of fibromyalgia according to the 2016 ACR diagnostic criteria
- Female patients aged 18-65
- Being literate
- Having signed the informed consent form upon agreeing to participate in the study
Exclusion Criteria:
- Being under 18 or over 65 years of age
- Having any condition that may lower the pain threshold or cause chronic pain (Rheumatoid Arthritis, Ankylosing Spondylitis, systemic inflammatory diseases, malignancies, etc.)
- Any neurological condition (stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, central nervous system malignancies…)
- Peripheral artery disease
- Severe cardiopulmonary insufficiency (stage 3-4)
- Uncontrolled systemic diseases such as hypertension and diabetes
- Presence of an active infection
- Pregnancy
- Presence of cognitive impairment, hearing loss, or communication difficulties that would prevent understanding of questionnaires and protocols
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Patient
Women with Fibromyalgia
|
including PPT Measurement with an Algometer, CPM and the Slow-Repeated Stimulated Pain Assessment Protocol
Central Sensitization Inventory, Revised Fibromyalgia Impact Questionnaire, S-LANSS, Tampa Kinesiophobia Scale, Hospital Anxiety and Depression Scale, SF-12 Quality of Life Scale and Fatigue Severity Scale
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Conditioned Pain Modulation
大体时间:Baseline
|
Objective determination of the pain modulation phenotype and the severity of central sensitization.
Scores above 100 are considered a normal CPM response; higher scores indicate greater pain inhibition.
|
Baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pressure Pain Threshold
大体时间:Baseline
|
Lower values are associated with pain sensitization
|
Baseline
|
|
Slowly Repeated Evoked Pain Assessment Protocol
大体时间:Baseline
|
The SREP protocol consists of 9 painful stimuli above the pain threshold, each applied to the nail for 5 seconds at approximately 30-second intervals.
|
Baseline
|
|
Central Sensitization Inventory
大体时间:Baseline
|
It is preferred for investigating pain sensitivity through symptoms associated with CS and related comorbidities.
CS severity can be classified into 5 different groups based on the score obtained from Section A of the scale: scores of 0-21 indicate a subclinical level, 22-30 indicate a mild level, 31-37 indicate a moderate level, 38-51 indicate a severe level, and scores above 51 indicate a very severe level of CS .
|
Baseline
|
|
Revised Fibromyalgia Impact Questionnaire
大体时间:Baseline
|
It consists of three sections-daily physical activities, general condition, and symptoms-and a total of 21 questions.
It assesses limitations and functional disability in patients with fibromyalgia.
All questions are rated on a 0-10-point Visual Analog Scale (VAS).
A higher total score indicates an increase in disability associated with fibromyalgia.
|
Baseline
|
|
Self-administered Leeds Assessment of Neuropathic Symptoms and Signs
大体时间:Baseline
|
The Neuropathic Symptoms and Signs Questionnaire is a 7-item self-report questionnaire completed by the individual, scored on a scale of 0 to 24.
A score of 12 or higher indicates the likelihood of neuropathic pain .
|
Baseline
|
|
Tampa Kinesiophobia Scale
大体时间:Baseline
|
A 17-item questionnaire developed to measure the fear of movement and re-injury .
The total score ranges from 17 to 68.
Higher scores are associated with an increase in kinesiophobia.
|
Baseline
|
|
Hospital Anxiety and Depression Scale
大体时间:Baseline
|
It consists of a total of 14 items, with 7 items each for anxiety and depression.
Scores for the anxiety and depression subscales range from 0 to 21. Scores between 8 and 10 indicate moderate symptom presence, while a score greater than 11 indicates anxiety and depression symptoms that likely correspond to a clinical diagnosis.
|
Baseline
|
|
SF-12 Quality of Life Scale
大体时间:Baseline
|
It was developed to assess health-related quality of life.
Two separate scores are obtained: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
The physical score reflects the individual's perception of overall health, physical limitations, and pain levels.
The mental score, on the other hand, reflects the individual's emotional problems, energy levels, and social activities.
|
Baseline
|
|
Fatigue Severity Scale
大体时间:Baseline
|
This is a 9-item questionnaire in which each item is rated on a scale of 1 to 7; it assesses the severity, frequency, and impact of fatigue on daily life.
The total score ranges from 7 to 63.
As the score decreases, fatigue decreases.
|
Baseline
|
合作者和调查者
调查人员
- 首席研究员:Feyza Nur Yücel, Assoc. Prof.、Saglik Bilimleri Universitesi
出版物和有用的链接
一般刊物
- Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016 Dec;46(3):319-329. doi: 10.1016/j.semarthrit.2016.08.012. Epub 2016 Aug 30.
- Yarnitsky D, Bouhassira D, Drewes AM, Fillingim RB, Granot M, Hansson P, Landau R, Marchand S, Matre D, Nilsen KB, Stubhaug A, Treede RD, Wilder-Smith OH. Recommendations on practice of conditioned pain modulation (CPM) testing. Eur J Pain. 2015 Jul;19(6):805-6. doi: 10.1002/ejp.605. Epub 2014 Oct 20.
- Maquet D, Croisier JL, Demoulin C, Crielaard JM. Pressure pain thresholds of tender point sites in patients with fibromyalgia and in healthy controls. Eur J Pain. 2004 Apr;8(2):111-7. doi: 10.1016/S1090-3801(03)00082-X.
- Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, Barton DL, St Sauver J. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. doi: 10.1002/acr.21896.
- Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021 Apr 9;22(8):3891. doi: 10.3390/ijms22083891.
- Nijs J, George SZ, Clauw DJ, Fernandez-de-Las-Penas C, Kosek E, Ickmans K, Fernandez-Carnero J, Polli A, Kapreli E, Huysmans E, Cuesta-Vargas AI, Mani R, Lundberg M, Leysen L, Rice D, Sterling M, Curatolo M. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol. 2021 May;3(5):e383-e392. doi: 10.1016/S2665-9913(21)00032-1. Epub 2021 Mar 30.
- Jurado-Priego LN, Cueto-Urena C, Ramirez-Exposito MJ, Martinez-Martos JM. Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies. Biomedicines. 2024 Jul 11;12(7):1543. doi: 10.3390/biomedicines12071543.
- Ruschak I, Monteso-Curto P, Rossello L, Aguilar Martin C, Sanchez-Monteso L, Toussaint L. Fibromyalgia Syndrome Pain in Men and Women: A Scoping Review. Healthcare (Basel). 2023 Jan 11;11(2):223. doi: 10.3390/healthcare11020223.
- de la Coba P, Bruehl S, Del Paso GAR. Addition of Slowly Repeated Evoked Pain Responses to Clinical Symptoms Enhances Fibromyalgia Diagnostic Accuracy. Pain Med. 2020 Dec 25;21(12):3479-3487. doi: 10.1093/pm/pnz346.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2026-94
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.